Samsung Biologics achieves 'Negligible Risk' rating in Sustainalytics ESG assessment
Samsung Biologics received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. The result places the company among the top 0.5% of companies assessed in the pharmaceuticals industry.
Primary source
Company press release (PR Newswire), November 3, 2026
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
Read the source: Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation